| APC/CTNNB1 mutant | APC/CTNNB1 wild type |
---|---|---|
Characteristics | Total (n = 55, %) | Total (n = 169, %) |
Sex | ||
 Male (%) | 35 (64) | 99 (59) |
 Female (%) | 20 (36) | 70 (31) |
Melanoma Type | ||
 Cutaneous (%) | 42 (76) | 123 (73) |
 Acral (%) | 5 (9) | 15 (9) |
 Mucosal (%) | 1 (2) | 14 (8) |
 Uveal (%) | 1 (2) | 0 (0) |
 Unknown Primary (%) | 6 (11) | 12 (7) |
 No information available (%) | 0 | 5 (3) |
Age at MM diagnosis median (range in years) | 61 (27–80) | 61 (21–99) |
Next Generation DNA sequencing Assay | ||
 Illumina 26-gene panel | 23 (42) | 0 |
 FoundationOne CDx | 32 (58) | 169 (100) |
Development of Brain Metastases | ||
 Yes (%) | 24 (44) | 66 (39) |
  Time to development from MM diagnosis (median, range in months) | 1.8 (0,96) | 8.6 (0,106.4) |
 No (%) | 31 (56) | 103 (61) |
Systemic Treatments-Immunotherapies | ||
 Yes (%) | 48 (87) | 151 (89) |
  Response (%) | 27 (56) | 63 (42) |
  Progression (%) | 20 (42) | 86 (57) |
  No information (%) | 1 (2) | 2 (1) |
 No (%) | 7 (13%) | 18 (11) |
Immunotherapy Types | ||
 Ipilimumab alone (%) | 1 (2) | 1 (1) |
 PD1 inhibitor alone (%) | 23 (48) | 90 (6) |
 Ipilimumab plus PD1 inhibitors (%) | 24 (50) | 59 (39) |
 High dose bolus IL-2 (%) | 1 (2) | 10 (7) |
 Other (IFNα2b) (%) | 3 (6) | 1 (1) |
Systemic Treatments-Non-immunotherapies | ||
 BRAF inhibitors and/or MEK inhibitors (%) | 16 (29) | 42 (25) |
 Other targeted therapies (%) | 5 (9) | 14 (8) |
 Chemotherapies (%) | 6 (11) | 25 (15) |
Genetic aberrations | ||
 Number of mutations/Mb* (median, range) APC/CTNNB1 genetic aberrations | 20 (2,372) | 13 (0,160) |
  CTNNB1 alone (%) | 29 (53) | N/A |
  APC alone (%) | 25 (45) | N/A |
 Both CTNNB1 and APC | 1 (2) | N/A |
Other mutations | ||
 BRAFV600 (%) | 19 (35) | 47 (28) |
  V600E | 16 (29) | 40 (24) |
  V600K | 3 (5) | 6 (4) |
  V600D | 0 | 1 (1) |
 BRAFK601 (%) | 1 (2) | 2 (1) |
 NRASQ61 (%)1 | 17 (31) | 36 (21) |